News

Bugworks secures funding from US Government's Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats

"We are very delighted to collaborate with DTRA and through them get the opportunity of working with intra-government agencies within the United States department of Defense, to advance BWC0977 as a potential single-stop solution against the most critical pathogens implicated in biothreats," added Anand Anandkumar, CEO of Bugworks.

Apr 26, 2021

By : Team ABLE

Bharat Biotech announces Covaxin price

Hyderabad-based Bharat Biotech International, the manufacturer of vaccine for COVID-19, announced prices for Covaxin.

Apr 24, 2021

By : Team ABLE

ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well

Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease

Apr 21, 2021

By : Team ABLE

After New Covid Vaccine Policy, Bharat Biotech to build the largest capacities for inactivated viral vaccine

Bharat Biotech Announces COVAXIN® Capacity Expansion to Support vaccination campaigns in India and Worldwide

Apr 21, 2021

By : Team ABLE

“We understand India’s needs,” says the US Government on vaccine’s raw material supply issues

The US Government responds to Serum’s request for allowing raw material and ingredients for Covid-19 vaccines. Mr Adar Poonawalla, CEO, Serum Institute of India (SII) had requested the US President Biden through a tweet asking the US to lift the embargo of raw material exports out of the US to ramp up vaccine production.

Apr 20, 2021

By : Team ABLE

 

Archives